NMDA encaphalitis etiology, mechanisms, Patho physiology, clinical feature, treatment and rescent update , standard source
Reading File
Finding Sources
Finding Sources
Searching PubMed
"anti-NMDA receptor encephalitis"[MeSH Terms]
Reading File
Reading File
Searching PubMed
"NMDA receptor encephalitis" AND treatment
Finding Sources
Reading Article
Reading Article
Finding Sources
Reading File
Searching the Web
anti-NMDA receptor encephalitis 2024 2025 treatment update guidelines rituximab
Reading File
Finding Sources
Reading Article
Reading File
Finding Sources
Now I have comprehensive information from multiple authoritative sources. Let me compile this into a thorough, well-structured response.
Anti-NMDA Receptor Encephalitis (NMDAR-E)
1. Etiology
Anti-NMDA receptor encephalitis (NMDAR-E) is an autoimmune encephalitis caused by IgG antibodies directed against the NR1 (GluN1) subunit of the N-methyl-D-aspartate receptor. It is now recognized as the most common form of autoimmune encephalitis, surpassing many viral causes in young adults.
Epidemiology:
- Predominantly affects young women (80% female), typically in their 20s, but cases occur across all ages including children and older adults
- Incidence has markedly risen in recent years - attributable to improved diagnostics rather than a true increase in prevalence
Tumor association (paraneoplastic trigger):
- Ovarian teratoma is the most common trigger, found in up to 50% of females under 45
- The teratoma harbors neural tissue expressing NMDA receptors, provoking an aberrant immune response
- Rarely: mediastinal teratoma, small cell lung cancer (including in men), breast cancer, or thymoma
- A significant proportion (~40%) have no detectable tumor - these are considered purely autoimmune
Non-paraneoplastic triggers:
- Viral infections (particularly HSV encephalitis can trigger NMDAR-E as a post-infectious phenomenon)
- No identifiable cause in many cases
(Adams and Victor's Principles of Neurology, 12th Ed.; Bradley and Daroff's Neurology in Clinical Practice)
2. Mechanism and Pathophysiology
The Antibody:
- Patients produce IgG autoantibodies against the GluN1 (NR1) subunit of the NMDAR - the obligatory subunit present in all functional NMDAR complexes
- Antibodies are found in both serum and CSF, with CSF titers being more diagnostically specific
- The antibody is directly pathogenic (not merely a biomarker)
Receptor-Level Mechanism:
NMDA receptors are ligand-gated ion channels permeable to Ca²⁺, Na⁺, and K⁺. They require:
- Glutamate binding
- Co-agonist glycine/D-serine binding
- Depolarization to relieve Mg²⁺ block
Anti-GluN1 antibodies cause reversible internalization and down-regulation of surface NMDA receptors via crosslinking and receptor endocytosis - this is distinct from direct channel blockade.
The GABAergic Interneuron Disinhibition Model:
NMDA receptors are concentrated on inhibitory GABAergic interneurons in the cortex and hippocampus. When these receptors are blocked/reduced:
- Inhibitory interneurons become hypofunctional
- Loss of inhibitory tone on glutamatergic pyramidal neurons (disinhibition)
- Net result: paradoxical cortical hyperexcitability despite NMDAR hypofunction
This mechanism explains the clinical syndrome - the psychiatric symptoms, psychosis, hyperkinesis, and seizures mirror what is seen with NMDAR antagonists like PCP (phencyclidine) or ketamine.
Why it's reversible:
Unlike antibodies targeting intracellular antigens (e.g., anti-Hu), which cause irreversible neuronal death, anti-NMDAR antibodies cause receptor down-regulation without direct cytotoxicity - hence the potential for full recovery with treatment.
CSF findings reflect ongoing inflammation:
- Lymphocytic pleocytosis in ~80% of patients
- Oligoclonal bands in many
- MRI: often normal, but can show T2/FLAIR hyperintensity in medial temporal lobes (limbic encephalitis pattern)
(Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Adams and Victor's Principles of Neurology; Bradley and Daroff's Neurology)
3. Clinical Features
The illness classically evolves through overlapping multistage phases:
Prodrome (days 1-5)
- Non-specific: low-grade fever, headache, malaise, fatigue, excessive sleepiness
- Can resemble a viral illness
Psychiatric / Psychotic Phase (days 5-20)
- Acute-onset psychiatric symptoms dominate the initial presentation - often prompting psychiatric admission
- Auditory and visual hallucinations
- Paranoid delusions
- Agitation, mood lability
- Behavioral disorganization
- Memory disturbance, cognitive impairment
- Echolalia, mutism
Neurological Phase (weeks 2-4)
- Seizures - generalized tonic-clonic or focal, in most patients
- Movement disorders - orofacial dyskinesias, choreoathetosis, dystonia; pathognomonic in context
- Decreased level of consciousness progressing to unresponsiveness or coma
- Catatonic features - waxy flexibility, posturing
- Autonomic instability - hypertension, tachycardia, diaphoresis, hypersalivation, pupillary changes, hyperthermia
- Central hypoventilation - often requiring mechanical ventilation
Outcome Phase
- Gradual recovery over weeks to months - but prolonged ICU stays are common
- ~80% of patients achieve good functional recovery with treatment
- Relapses occur in ~12-25% of cases
Key diagnostic clues:
- Young woman + new-onset psychosis + seizures + movement disorder = NMDAR-E until proven otherwise
- Symptoms often misdiagnosed as schizophrenia, drug intoxication, or viral encephalitis
- EEG shows epileptiform discharges, generalized slowing, or pathognomonic "extreme delta brush" pattern in severe cases
(Adams and Victor's, Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Plum and Posner's Diagnosis and Treatment of Stupor and Coma)
4. Diagnosis
| Investigation | Finding |
|---|---|
| Serum anti-GluN1 antibodies | Positive - high sensitivity for screening |
| CSF anti-GluN1 antibodies | More specific; can be positive when serum is negative |
| CSF routine | Lymphocytic pleocytosis (80%), elevated protein, oligoclonal bands |
| MRI brain | Often normal; T2/FLAIR hyperintensity in mesiotemporal regions in ~30-40% |
| EEG | Generalized slowing, epileptiform discharges, extreme delta brush |
| FDG-PET | Mesiotemporal and striatal hypermetabolism early; hypometabolism later |
| Pelvic ultrasound/CT | Screen for ovarian teratoma |
| Whole-body PET/CT | Tumor screening when ultrasound negative |
(Bradley and Daroff's Neurology; Kaplan & Sadock's Comprehensive Textbook of Psychiatry)
5. Treatment
Treatment follows a stepwise immunotherapy approach combined with tumor removal.
First-Line Therapy (initiated promptly)
| Treatment | Regimen | Rationale |
|---|---|---|
| Tumor removal | Oophorectomy (if teratoma found) | Removes the immunogenic trigger; most effective intervention |
| High-dose IV methylprednisolone | 1 g/day x 5 days | Anti-inflammatory |
| IV immunoglobulin (IVIG) | 0.4 g/kg/day x 5 days | Antibody neutralization |
| Plasma exchange (PLEX) | 5-7 exchanges | Antibody removal |
IVIG and PLEX are roughly equivalent and can be used together or sequentially. Improvement after tumor removal is associated with declining antibody titers over weeks.
Second-Line Therapy (for refractory or severe cases)
| Treatment | Notes |
|---|---|
| Rituximab | Anti-CD20 monoclonal antibody; depletes B cells; most evidence-based second-line agent |
| Cyclophosphamide | Often combined with rituximab in severe cases |
| Mycophenolate mofetil / Azathioprine | Long-term maintenance immunosuppression |
~25% of cases are refractory to first-line treatment and require second-line agents. Early initiation of immunotherapy significantly improves outcomes (Titulaer et al., Lancet Neurology 2013).
Symptomatic Management
- Anti-seizure medications (levetiracetam preferred)
- Benzodiazepines for agitation
- ICU care and mechanical ventilation for autonomic instability and hypoventilation
- Avoid antipsychotics if possible - may worsen dyskinesias (though low-dose may be needed for severe agitation)
(Plum and Posner's; Adams and Victor's; Kaplan & Sadock's; Bradley and Daroff's Neurology)
6. Recent Updates (2023-2025)
ExTINGUISH Trial - Inebilizumab (2025)
A Phase 2B double-blind RCT (NIH-funded, international) is testing inebilizumab - a monoclonal antibody against CD19 that provides more comprehensive and sustained B-cell depletion than rituximab. Unlike rituximab (anti-CD20), inebilizumab targets CD19+ B cells including plasmablasts. Results are awaited and could shift second-line treatment. ExTINGUISH trial details
CAAR T-Cell Therapy (Cell, 2023) - PMID 37918394
Reincke et al. developed chimeric autoantibody receptor (CAAR) T cells engineered to selectively eliminate anti-NMDAR B cells. These NMDAR-CAAR T cells:
- Recognize patient-derived anti-NMDAR autoantibodies
- Selectively kill autoantigen-specific B cells without broad immunosuppression
- Reduce autoantibody levels in murine models without off-target toxicity
- Pave the way for Phase I/II trials - a potentially disease-specific precision treatment
Intrathecal Rituximab (2024)
For refractory cases failing IV rituximab, intrathecal rituximab administration has shown rapid recovery in case series, targeting the intrathecal B-cell compartment directly.
Ofatumumab + Daratumumab Combination (2025)
Case reports of combination anti-CD20 (ofatumumab) and anti-CD38 (daratumumab) therapy in severe refractory cases, targeting both B cells and long-lived plasma cells that survive rituximab.
Updated Meta-Analysis (2025 - ScienceDirect)
A comprehensive meta-analysis confirmed:
- No FDA-approved treatments exist for anti-NMDAR encephalitis as of 2025
- Early use of first- and second-line immunotherapy has increased significantly since 2019
- Long-term functional outcomes in children are favorable with early treatment
Key 2025 Review (Dalmau & Guasp, Med Clin North Am, PMID 39893022)
Authored by Josep Dalmau (the researcher who first described this condition), this review reaffirms NMDAR-E as the most frequent autoimmune encephalitis and emphasizes that prompt diagnosis + treatment leads to substantial recovery in most patients.
Summary Table
| Aspect | Key Points |
|---|---|
| Antibody | IgG anti-GluN1 (NR1 subunit of NMDAR) |
| Demographics | Young women; all ages possible |
| Trigger | Ovarian teratoma (50% in women <45), no tumor (~40%) |
| Mechanism | Receptor internalization → GABAergic interneuron hypofunction → disinhibition |
| Stages | Prodrome → Psychiatric → Neurological → Recovery |
| Hallmarks | Psychosis + seizures + orofacial dyskinesias + autonomic instability |
| Diagnosis | CSF/serum anti-GluN1 Ab; CSF pleocytosis; EEG; MRI |
| First-line Rx | Tumor removal + steroids + IVIG/PLEX |
| Second-line Rx | Rituximab ± cyclophosphamide |
| Emerging Rx | Inebilizumab (ExTINGUISH trial), CAAR T cells, intrathecal rituximab |
| Prognosis | ~80% good recovery; ~20% relapse risk; reversible if treated early |
Sources:
- Adams and Victor's Principles of Neurology, 12th Ed.
- Bradley and Daroff's Neurology in Clinical Practice
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry
- Plum and Posner's Diagnosis and Treatment of Stupor and Coma
- Harrison's Principles of Internal Medicine, 22nd Ed. (2025)
- Dalmau J et al. - original case series (Lancet Neurology, 2008)
- Titulaer MJ et al. - treatment and prognosis (Lancet Neurology, 2013)
- Reincke SM et al. - CAAR T cells (Cell, 2023) [PMID: 37918394]
- Guasp M, Dalmau J - Autoimmune Encephalitis review (Med Clin North Am, 2025) [PMID: 39893022]
- Padureanu V et al. - Narrative Review (Brain Sci, 2025) [PMID: 40426689]
- ExTINGUISH Trial - inebilizumab Phase 2B (Neurology Open Access, 2025)
Can you provide full answer
Asking for Preferences
Reading File
Running Command
Running Command
Writing File
Running Command
Running Command
Your PDF is ready. Here is the download link:
NMDA Receptor Encephalitis
PDF Document · PDF
What the PDF covers (10 fully formatted sections):
- Overview & Definition - What NMDAR-E is and why it matters
- Etiology - Tumor-associated triggers (ovarian teratoma, SCLC), non-paraneoplastic causes, post-HSV NMDAR-E, epidemiology
- Molecular Mechanisms - NMDAR structure, antibody-mediated internalization, the GABAergic disinhibition circuit (step-by-step table), complement/T-cell contributions
- Pathophysiology - Hippocampal, striatal, autonomic, and cortical involvement; neuroimaging correlates table
- Clinical Features - The 5-stage multistage progression table, detailed psychiatric and neurological features, features by population (children, males, elderly, post-HSV)
- Diagnosis - Graus 2016 criteria, full investigations table, comprehensive differential diagnosis table
- Treatment - First-line (steroids, IVIG, PLEX, tumor removal), second-line (rituximab, cyclophosphamide, bortezomib, intrathecal rituximab), symptomatic management, treatment algorithm table, fertility considerations
- Prognosis - Outcome metrics table, prognostic factors
- Recent Updates (2023–2025) - ExTINGUISH trial (inebilizumab), CAAR T-cell therapy (Cell 2023), intrathecal rituximab, ofatumumab+daratumumab, updated meta-analysis, skull meningeal channel pathophysiology, pediatric long-term outcomes
- References - 15 standard sources including Adams & Victor's, Harrison's 22nd Ed., Bradley & Daroff's, Kaplan & Sadock's, Plum & Posner's, and key PubMed papers (2023–2025)
This is a shared conversation. Sign in to Orris to start your own chat.